213 related articles for article (PubMed ID: 37946202)
1. Inhibition of USP7 upregulates USP22 and activates its downstream cancer-related signaling pathways in human cancer cells.
Zhang K; Sun T; Li W; Guo Y; Li A; Hsieh M; Wang J; Wu J; Arvanitis L; Raz DJ
Cell Commun Signal; 2023 Nov; 21(1):319. PubMed ID: 37946202
[TBL] [Abstract][Full Text] [Related]
2. Ubiquitin-specific protease 22 is critical to in vivo angiogenesis, growth and metastasis of non-small cell lung cancer.
Zhang K; Yang L; Wang J; Sun T; Guo Y; Nelson R; Tong TR; Pangeni R; Salgia R; Raz DJ
Cell Commun Signal; 2019 Dec; 17(1):167. PubMed ID: 31842906
[TBL] [Abstract][Full Text] [Related]
3. USP7 facilitates SMAD3 autoregulation to repress cancer progression in p53-deficient lung cancer.
Huang YT; Cheng AC; Tang HC; Huang GC; Cai L; Lin TH; Wu KJ; Tseng PH; Wang GG; Chen WY
Cell Death Dis; 2021 Sep; 12(10):880. PubMed ID: 34580281
[TBL] [Abstract][Full Text] [Related]
4. USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis.
Fan YH; Cheng J; Vasudevan SA; Dou J; Zhang H; Patel RH; Ma IT; Rojas Y; Zhao Y; Yu Y; Zhang H; Shohet JM; Nuchtern JG; Kim ES; Yang J
Cell Death Dis; 2013 Oct; 4(10):e867. PubMed ID: 24136231
[TBL] [Abstract][Full Text] [Related]
5. Histone H2B monoubiquitination: roles to play in human malignancy.
Cole AJ; Clifton-Bligh R; Marsh DJ
Endocr Relat Cancer; 2015 Feb; 22(1):T19-33. PubMed ID: 24891457
[TBL] [Abstract][Full Text] [Related]
6. USP7 Inhibition Suppresses Neuroblastoma Growth via Induction of p53-Mediated Apoptosis and EZH2 and N-Myc Downregulation.
Le Clorennec C; Lee K; Huo Y; Zage PE
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762082
[TBL] [Abstract][Full Text] [Related]
7. Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells.
Colland F; Formstecher E; Jacq X; Reverdy C; Planquette C; Conrath S; Trouplin V; Bianchi J; Aushev VN; Camonis J; Calabrese A; Borg-Capra C; Sippl W; Collura V; Boissy G; Rain JC; Guedat P; Delansorne R; Daviet L
Mol Cancer Ther; 2009 Aug; 8(8):2286-95. PubMed ID: 19671755
[TBL] [Abstract][Full Text] [Related]
8. Transcription factor AP2 enhances malignancy of non-small cell lung cancer through upregulation of USP22 gene expression.
Sun T; Zhang K; Li W; Liu Y; Pangeni RP; Li A; Arvanitis L; Raz DJ
Cell Commun Signal; 2022 Sep; 20(1):147. PubMed ID: 36123698
[TBL] [Abstract][Full Text] [Related]
9. Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism.
Schauer NJ; Liu X; Magin RS; Doherty LM; Chan WC; Ficarro SB; Hu W; Roberts RM; Iacob RE; Stolte B; Giacomelli AO; Perera S; McKay K; Boswell SA; Weisberg EL; Ray A; Chauhan D; Dhe-Paganon S; Anderson KC; Griffin JD; Li J; Hahn WC; Sorger PK; Engen JR; Stegmaier K; Marto JA; Buhrlage SJ
Sci Rep; 2020 Mar; 10(1):5324. PubMed ID: 32210275
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a Potent and Selective Degrader for USP7.
Pei Y; Fu J; Shi Y; Zhang M; Luo G; Luo X; Song N; Mi T; Yang Y; Li J; Zhou Y; Zhou B
Angew Chem Int Ed Engl; 2022 Aug; 61(33):e202204395. PubMed ID: 35691827
[TBL] [Abstract][Full Text] [Related]
11. USP7 inhibitor P5091 inhibits Wnt signaling and colorectal tumor growth.
An T; Gong Y; Li X; Kong L; Ma P; Gong L; Zhu H; Yu C; Liu J; Zhou H; Mao B; Li Y
Biochem Pharmacol; 2017 May; 131():29-39. PubMed ID: 28216017
[TBL] [Abstract][Full Text] [Related]
12. Ubiquitin-specific protease 7 (USP7): an emerging drug target for cancer treatment.
Carreira LD; Oliveira RI; Moreira VM; Salvador JAR
Expert Opin Ther Targets; 2023; 27(11):1043-1058. PubMed ID: 37789645
[TBL] [Abstract][Full Text] [Related]
13. The USP7 Inhibitor P5091 Induces Cell Death in Ovarian Cancers with Different P53 Status.
Wang M; Zhang Y; Wang T; Zhang J; Zhou Z; Sun Y; Wang S; Shi Y; Luan X; Zhang Y; Wang Y; Wang Y; Zou Z; Kang L; Liu H
Cell Physiol Biochem; 2017; 43(5):1755-1766. PubMed ID: 29049989
[TBL] [Abstract][Full Text] [Related]
14. USP7 deubiquitinase promotes ubiquitin-dependent DNA damage signaling by stabilizing RNF168.
Zhu Q; Sharma N; He J; Wani G; Wani AA
Cell Cycle; 2015; 14(9):1413-25. PubMed ID: 25894431
[TBL] [Abstract][Full Text] [Related]
15. Loss of H2B monoubiquitination is associated with poor-differentiation and enhanced malignancy of lung adenocarcinoma.
Zhang K; Wang J; Tong TR; Wu X; Nelson R; Yuan YC; Reno T; Liu Z; Yun X; Kim JY; Salgia R; Raz DJ
Int J Cancer; 2017 Aug; 141(4):766-777. PubMed ID: 28481029
[TBL] [Abstract][Full Text] [Related]
16. Immune Evasion and Drug Resistance Mediated by USP22 in Cancer: Novel Targets and Mechanisms.
Guo J; Zhao J; Fu W; Xu Q; Huang D
Front Immunol; 2022; 13():918314. PubMed ID: 35935969
[TBL] [Abstract][Full Text] [Related]
17. USP7 targets XIAP for cancer progression: Establishment of a p53-independent therapeutic avenue for glioma.
Saha G; Sarkar S; Mohanta PS; Kumar K; Chakrabarti S; Basu M; Ghosh MK
Oncogene; 2022 Nov; 41(47):5061-5075. PubMed ID: 36243803
[TBL] [Abstract][Full Text] [Related]
18. Targeting USP22 Suppresses Tumorigenicity and Enhances Cisplatin Sensitivity Through ALDH1A3 Downregulation in Cancer-Initiating Cells from Lung Adenocarcinoma.
Yun X; Zhang K; Wang J; Pangeni RP; Yang L; Bonner M; Wu J; Wang J; Nardi IK; Gao M; Raz DJ
Mol Cancer Res; 2018 Jul; 16(7):1161-1171. PubMed ID: 29720480
[TBL] [Abstract][Full Text] [Related]
19. Dissenting degradation: Deubiquitinases in cell cycle and cancer.
Bonacci T; Emanuele MJ
Semin Cancer Biol; 2020 Dec; 67(Pt 2):145-158. PubMed ID: 32201366
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of USP7 induces p53-independent tumor growth suppression in triple-negative breast cancers by destabilizing FOXM1.
Yi J; Li H; Chu B; Kon N; Hu X; Hu J; Xiong Y; Kaniskan HU; Jin J; Gu W
Cell Death Differ; 2023 Jul; 30(7):1799-1810. PubMed ID: 37291217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
